Pfizer and Grameen health to improve Bangladeshi health delivery
This article was originally published in Scrip
Executive Summary
Pfizerand the micro-financing organisation Grameen Health are to work together to improve healthcare delivery systems and primary care clinics in Bangladesh. The companies expect that if a successful business model is developed, it could then be used in other developing countries. Addressing the needs of those whose annual income is less than $3,000 is a priority of the partnership.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.